Basilea Pharmaceutica Ltd. Logo
 
 
News and Media
 
 
Search
 ›› go!
 

Anti-Infectives 2010

 
 
 

Ceftobiprole  

  • Betriu C, Culebras E, Gómez M, López-Fabal F, Rodríguez-Avial I, Picazo JJ. Comparative in vitro activity of ceftobiprole against Gram-positive cocci. Int J Antimicrob Agents. 2010; 36(2): 111-113.
  • Borbone S, Campanile F, Bongiorno D, Stefani S. In vitro bactericidal activity of ceftobiprole against hospital- and community-associated methicillin resistant Staphylococcus aureus. J Antimicrob Chemother. 2010; 65(3): 591-594.
  • Bustos C, del Pozo JL. Emerging agents to combat complicated and resistant infections: Focus on ceftobiprole. Infect Drug Resist. 2010; 3(1): 5-14.  
  • Cattoir V, Daurel C. Update on antimicrobial chemotherapy. Med Mal Infect. 2010; 40(3): 135-154.
  • Curcio D. New antibiotics: Which role in a antimicrobial stewardship program? Int J Infect Dis. 2010; 14: e315.
  • Fernandez J, Hilliard JJ, Abbanat D, Zhang W, Melton JL, Santoro CM, Flamm RK, Bush K. In vivo activity of ceftobiprole in murine skin infections due to Staphylococcus aureus and Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2010; 54(1): 116-125.
  • Henry X, Amoroso A, Coyette J, Joris B. Interaction of ceftobiprole with the low-affinity PBP 5 of Enterococcus faecium. Antimicrob Agents Chemother. 2010; 54(2): 953-955.
  • Nannini EC, Stryjewski ME, Singh KV, Rude TH, Ralph Corey G, Fowler Jr VG, Murray BE. Determination of an inoculum effect with various cephalosporins among clinical isolates of methicillin-susceptible Staphylococcus aureus. Antimicrob Agents Chemother. 2010; 54(5): 2206-2208.  
  • Shang W, Davies TA, Flamm RK, Bush K. Effects of ceftobiprole and oxacillin on mecA expression in methicillin-resistant Staphylococcus aureus clinical isolates. Antimicrob Agents Chemother. 2010; 54(2): 956-959.
  • Silva N, Radhouani H, Gonçalves A, Araújo C, Rodrigues J, Igrejas G, Poeta P. In vitro activity of ceftobiprole against Gram-positive and Gram-negative bacteria isolated from humans and animals. J Antimicrob Chemother. 2010; 65(4): 801-803.  
  • Tattevin P, Basuino L, Bauer D, Diep BA, Chambers HF. Ceftobiprole is superior to vancomycin, daptomycin, and linezolid for treatment of experimental endocarditis in rabbits caused by methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 2010; 54(2): 610-613.

 

20th European Congress of Clinical Microbiology and Infectious Diseases ECCMID, April 2010, Vienna, Austria

 
  • P-939 / Trends in ceftobiprole susceptibility among 2001-2008 consecutive methicillin-resistant Staphylococcus aureus blood isolates. Golan Y, McDermott L, Snydman DR.
  • P-1226 / Effect of ceftobiprole on the normal human intestinal microflora. Panagiotidis G, Bäckström T, Asker-Hagelberg C, Rashid M, Weintraub A, Nord CE.
  • P-1269 / Susceptibility of Gram-negative pathogens to ceftobiprole, ceftazidime and cefepime isolated from centres in Austria, Germany and Switzerland. Seifert H, Gatermann S, Pfister W, Poehlmann C, Huhulescu S, Muehlemann K, Laeuffer J, Decker-Burgard S, Cassettari M, Morrissey I.
  • P-1875 / Ceftobiprole activity when tested against clinical bacterial pathogens from Europe, 2009. Farrell D, Moet G, Sader H, Putnam S, Jones R. 

Isavuconazole

  • Farowski F, Cornely OA, Vehreschild JJ, Hartmann P, Bauer T, Steinbach A, Rüping MJGT, Müller C.  Quantitation of azoles and echinocandins in compartments of peripheral blood by liquid chromatography-tandem mass spectrometry. Antimicrob Agents Chemother. 2010; 54(5): 1815-1819.
  • Guinea J, Recio S, Escribano P, Torres-Narbona M, Peláez T, Sánchez-Carrillo C, Rodríguez-Créixems M, Bouza E. Rapid antifungal susceptibility determination for yeast isolates by use of Etest performed directly on blood samples from patients with fungemia. J Clin Microbiol. 2010; 48(6): 2205-2212.
  • Najafzadeh MJ, Badali H, Illnait-Zaragozi MT, De Hoog GS, Meis JF. In vitro activities of eight antifungal drugs against 55 clinical isolates of Fonsecaea spp. Antimicrob Agents Chemother. 2010; 54(4): 1636-1638.
  • Pasqualotto AC, Thiele KO, Goldani LZ. Novel triazole antifungal drugs: Focus on isavuconazole, ravuconazole and albaconazole. Curr Opin Invest Drugs. 2010; 11(2): 164-174.
 

20th European Congress of Clinical Microbiology and Infectious Diseases ECCMID, April 2010, Vienna, Austria

 
  • P-838 / Antifungal susceptibility of yeasts isolated from patients with fungaemia: comparison of the E-test on direct blood samples and CLSI M27-A3. Guinea J, Recio S, Escribano P, Peláez T, Torres-Narbona M, Rodríguez-Créixems M, Sánchez-Carrillo C, Bouza E.
  • P-839 / Can isavuconazole MICs for yeasts be read after 24 hours of incubation? Guinea J, Escribano P, Recio S, Peláez T, Bouza E.
  • P-840 / In vitro activity of isavuconazole against clinical non-Candida yeast isolates determined by E-test and CLSI M27-A3. Guinea J, Recio S, Escribano P, Peláez T, Bouza E.
 

Research

20th European Congress of Clinical Microbiology and Infectious Diseases ECCMID, April 2010, Vienna, Austria

 
  • P-1240 / Efficacy of BAL30072, alone and combined with meropenem, against VIM-producing enterobacteria in a murine thigh infection model. Miriagou V, Papagiannitsis C, Kotsakis S, Zioga A, Siatravani E, Loli A, Tzelepi E, Tzouvelekis T, Donzelli M, Spickermann J, Page M.  
  • P-1241 / The role of iron transport in the activity of the siderophore sulfactam BAL30072 against Pseudomonas aeruginosa. Page M, Müller C, Hofer B, Desarbre E, Dreier J, Vidal F.
 

 

Info